18 studies found for:    "Hemophagocytic lymphohistiocytosis"
Show Display Options
Rank Status Study
1 Unknown  Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
Conditions: Chediak-Higashi Syndrome;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: filgrastim;   Drug: methotrexate;   Procedure: allogeneic hematopoietic stem cell transplantation
2 Recruiting Administration of Donor T Cells With the Caspase-9 Suicide Gene
Conditions: Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Non Hodgkin Lymphoma;   Hemophagocytic Lymphohistiocytosis;   Familial Hemophagocytic Lymphohistiocytosis;   Hemophagocytic Syndrome;   Epstein Barr Virus Infection;   X-linked Lymphoproliferative Disease
Interventions: Biological: Allodepleted T Cells Transduced with iCaspase9 Suicide Gene;   Drug: AP1903
3 Recruiting T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Conditions: Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
Interventions: Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
4 Terminated Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Conditions: Immunologic Deficiency Syndromes;   Chediak-Higashi Syndrome;   Common Variable Immunodeficiency;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   X-linked Hyper IgM Syndrome;   Severe Combined Immunodeficiency;   Leukocyte Adhesion Deficiency Syndrome;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Allogeneic Bone Marrow Transplantation
5 Recruiting Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: ATG, rabbit;   Drug: Etoposide;   Drug: Intrathecal Methotrexate;   Drug: hydrocortisone
6 Recruiting Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Intervention: Drug: IHT and alloHCT
7 Active, not recruiting Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: Dexamethasone;   Drug: Etoposide;   Drug: Cyclosporin;   Procedure: Intrathecal therapy;   Procedure: Stem cell transplant
8 Recruiting A Study to Investigate the Safety and Efficacy of a New Drug in Children With a Disease That is Called "Reactivated Primary Haemophagocytic Lymphohistiocytosis"
Condition: Primary Hemophagocytic Lymphohistiocytosis
Interventions: Biological: NI-0501;   Drug: Dexamethasone;   Drug: Cyclosporine A
9 Recruiting Trial of DA-EPOCH Regimen for NHL With HLH
Condition: NHL With Hemophagocytic Lymphohistiocytosis
Intervention: Drug: DA-EPOCH
10 Unknown  Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis
Condition: Nonneoplastic Condition
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: dexamethasone;   Drug: etoposide;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: therapeutic hydrocortisone;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: biopsy
11 Active, not recruiting T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
Conditions: Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Diseases;   Langerhans-Cell Histiocytosis;   Hematologic Diseases
Interventions: Procedure: Stem Cell Transplant;   Drug: Myeloablative conditioning regimen
12 Active, not recruiting Stem Cell Transplant for Immunologic or Histiocytic Disorders
Conditions: Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Deficiency Syndromes;   Langerhans-Cell Histiocytosis
Interventions: Procedure: Stem Cell Transplant;   Drug: Fludarabine, melphalan, ATG or Campath
13 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Aggamaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
14 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: Severe Combined Immunodeficiency;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   MHC Class II Deficiency;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Combined Immune Deficiencies;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
15 Recruiting Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity
Condition: Hemophagocytic Lymphohisticytosis
Intervention: Other: blood sample
16 Active, not recruiting CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Conditions: Acute Lymphoblastic Leukemia;   Non-Hodgkin's Lymphoma
Intervention: Biological: Allodepleted T Cells
17 Active, not recruiting Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: in situ hybridization;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: medical chart review
18 Recruiting Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Condition: Nonmalignant Neoplasm
Interventions: Procedure: umbilical cord blood transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Drug: fludarabine phosphate;   Drug: treosulfan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: methotrexate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Genetic: DNA analysis;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis;   Biological: anti-thymocyte globulin

Indicates status has not been verified in more than two years